PERPETUAL EQUITY INVESTMENT COMPANY LIMITED

INVESTOR UPDATE

November 2017

Perpetual

IMPORTANT NOTE



This information was prepared by Perpetual Investment Management Limited (PIML) ABN 18 000 866 535, AFSL 234426 and issued by Perpetual Trustee Company Limited (PTCL) ABN 42 000 001 007, AFSL 236643. PIML is the Manager for the Perpetual Equity Investment Company Limited (Company) ACN 601 406 419.

This publication does not constitute nor does it contain an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in the Company. The information contained in this publication has been prepared for the purpose of providing general information only. It does not take into account the particular objectives, financial situation or needs for investment of any investor, or purport to be comprehensive or constitutive investment advice and should not be relied upon as such. Before making an investment in the Company or acting on the information in this publication, you should consider, with your financial adviser, whether any investment decision is appropriate having regard to your individual objectives, financial situation and needs.

References to securities in this publication are for illustrative purposes only, and are not recommendations and the securities may or may not be currently held by the Company. Past performance is not indicative of future performance.

The information in this publication is believed to be accurate at the time of compilation and is provided in good faith. To the extent permitted by law, no liability is accepted for any loss or damage as a result of any reliance on this information. The Company, PIML, PTCL nor any company in the Perpetual Group warrants or guarantees the performance of, or any return on an investment made in, the Company. Perpetual Group means Perpetual Limited ABN 86 000 431 827 and its subsidiaries.

YOUR PRESENTERS



NANCY FOX

Chairman, Perpetual Equity Investment Company limited



VINCE PEZZULLO Portfolio Manager, Perpetual Investments

SYDNEY

Thursday, 2 November 2017 1.45pm for 2.00pm, to conclude by 4.00pm Perpetual Offices, Angel Place Level 18, 123 Pitt Street, Sydney

MELBOURNE

Wednesday, 29 November 2017 10.15am for 10.30am, to conclude by 11.30am Perpetual Offices, Rialto South Tower Level 35, 525 Collins Street

YOUR PRESENTERS



NICK BUISMAN Investment Specialist, Perpetual Investments



VINCE PEZZULLO Portfolio Manager, Perpetual Investments

PERPETUAL EQUITY INVESTMENT COMPANY

ADELAIDE

Wednesday, 15 November 2017 10.15am for 10.30am, to conclude by 11.30am Perpetual Offices,

Level 11, 101 Grenfell Street, Adelaide

BRISBANE

Tuesday, 21 November 2017 10.15am for 10.30am, to conclude by 11.30am Perpetual Offices, Central Plaza 1 Level 15, 345 Queen Street, Brisbane

YOUR PRESENTER



NICK BUISMAN

Investment Specialist, Perpetual Investments

PERTH

Thursday, 16 November 2017 10.15am for 10.30am, to conclude by 11.30am Perpetual Offices, Exchange Tower Level 29, 2 The Esplanade, Perth

PERPETUAL EQUITY INVESTMENT

AGENDA

PERPETUAL EQUITY INVESTMENT COMPANY


Company Update

Markets, Process And Performance

Questions

Shareholder Services





COMPANY UPDATE



INVESTING FOR REGULAR INCOME AND LONG-TERM CAPITAL GROWTH PIC: MANAGER WITH PROVEN TRACK RECORD



Actively managed by Perpetual investment professionals



Concentrated 20 – 40 stock portfolio



Access to high quality Australian and global listed securities (typically mid-cap)



Benchmark and sector unaware

INVESTMENT OBJECTIVES


- Deliver a growing income stream
- Provide long term capital growth
- Exceed its benchmark

PORTFOLIO MANAGER – VINCE PEZZULLO

- 20+ years in financial services industry
- Extensive domestic and global equity experience

FULL YEAR 2017 OVERVIEW STRONG RESULTS AND INCREASED DIVIDEND





Operating profit after tax

\$31.8m 4.7 cents

Per share fully franked dividend

\$1.097*

Net tangible assets after tax per share

17.4%^

Investment performance 1 year to 30 June 2017

Source: Perpetual Equity Investment Company Limited (PIC) as at 30 June 2017.

*'After tax' refers to after tax paid and provisions for deferred tax on set-up costs and on unrealised gains and losses in the company's investment portfolio.

^ Returns have been calculated on the growth of Net Tangible Assets (NTA) after taking into account all operating expenses (including management fees) and assuming reinvestment of dividends and excluding tax paid. Past performance is not indicative of future performance. The benchmark is the S&P/ASX 300 Accumulation Index. Past performance is not indicative of future performance. 9

PROVEN TRACK RECORD





Established in 1886, Perpetual is one of Australia's **most respected** fund managers, with a passion for **protecting** and **growing** our clients' wealth



Perpetual is an active, value manager, with a bottom-up investment process



One of the largest investment teams in Australia that conducts **more than 1,000 company meetings** each year



\$31.4bn funds under management (at 30 June 2017)



Perpetual Investments is part of Perpetual Limited (ASX:PPT)



Provider of market-leading equities, fixed income, cash and multi asset solutions

Source: Perpetual Investment Management Limited

KEEPING YOU INFORMED WITH EXCELLENT SERVICE



www.perpetualequity.com.au



Monthly emails including market updates



Daily NTA announcement




Half year and full year financial results



Half yearly national investor presentations and broker roundtables

PERPETUAL EQUITY INVESTMENT COMPANY



Source: FactSet, RBC - as at 26 Oct '17


Pre tax NTA returns shown for the Company have been calculated on the growth of Net Tangible Assets (NTA) after taking into account all operating expenses (including management fees and any income tax on realised gains) and assuming reinvestment of dividends. Any provisions for deferred tax on set up costs and on unrealised gains and losses are excluded. Past performance is not indicative of future performance. Inception date is 18 December 2014.



MARKETS, PROCESS AND PERFORMANCE



WHERE ARE WE AT TODAY? PRICE TO EARNINGS **MULTIPLE CURRENT V 10 YR. AVERAGE ASX 200**



PERPETUAL


EQUITY INVESTMENT COMPANY

FY17 REPORTING SEASON OVERVIEW MARGINS



Margins have already risen a lot from the FY14 trough, so its not surprising that forecasts have been trimmed a little

Cyclical industrial margins are already close to previous peaks



THE SYSTEMATIC RISK IN "LOW VOL" STOCKS SITS AT A 20-YEAR HIGH


PERPETUAL EQUITY INVESTMENT COMPANY

Prices of what are considered "low volatility" stocks have risen

Buying today you are taking on close to market risk


Low volatility stocks include:

Telstra, Transurban, Scentre Group, CBA, Stockland, GPT, NAB, ANZ, Westpac, APA, Mirvac, Spark Infrastructure, Suncorp, Investa Office Fund, CSL.



Source: Goldman Sachs Global Investment Research, FactSet, IRESS, I/B/E/S

HAVE WE CONSIDERED THE RIGHT RISKS? THE RISE OF PASSIVE CAN HAVE IMPLICATIONS



Source: Bloomberg LP (which owns Bloomberg BusinessWeek) and its affiliates provide indexes tracking various asset classes. Data: Bloomberg Intelligence, Sandford C Bernstein, World Bank, Cash Flows as of March 31. Graphic created by Bloomberg BusinessWeek. PERPETUAL

EQUITY INVESTMENT COMPANY

OUR INVESTMENT PHILOSOPHY QUALITY & VALUE FOCUS




OUR FOCUS1Quality business3Sound management2Conservative debt4Recurring earnings

THIS MEANS:



We seek quality companies at attractive valuations





SHIRE PLC - SHARE PRICE (GBP)

FORWARD P/E MULTIPLES (x)



Source: FactSet, as at 27 Oct 2017

Source: Perpetual Investment Management Limited



IDEA IDENTIFICATION

OPPORTUNITY

 Share price weakness stemming from market concerns around competition from Roche ACE910 impacting sales in Shire's haemophilia franchise.

SCREENING

- Compared well quantitatively with market and peers
- Initially ticked a lot of boxes:
 - **Understandable business** diversified rare disease company, exposure to 7 therapeutic areas.
 - Strong market share leading Bioplasma company, strong share of global IVIG market (3Q IVIG sales +21% y/y).
 - **Growing sales** strong revenue growth in recent years, combination of organic and acquired, looking to monetise R & D investment over the next several years.
 - Generating free cash strong cash generation, deleveraging
 - Sound management Chairwoman highly regarded, Board focused on debt reduction; CEO joined in 2012, has rationalised and optimised the business.

Q

IN-DEPTH, FUNDAMENTAL RESEARCH

MAJOR CONCERNS

- Haemophilia franchise sales to halve over the next 2-3 years
- Immunology business underappreciated
- Threat to Lialda business from generics
- M&A concerns around sale of neuroscience business

WORK

- Proprietary survey conducted with US, UK and German physicians indicated high level of conservatism, desire to see a track record of safety data before switching clients.
- Call with infusion clinic specialist on infusion economics
- Contact with variety of industry experts HAE specialists, IVIG Clinician, Global Health Tender Market expert, clinicians, ex-employees, FDA, founder of competitor product



PROPRIETARY SURVEY

KEY RESULTS

- Inhibitor patient share loss of at most 25% within 5 years time
 - **45% physicians** would switch ~25% inhibitor clients to ACE910 within 5 years (only 6% would switch>25%)
- Non-inhibitor patient share loss of 5-10% within 2 years time, and most likely 10-15% within 5 years time
 - **65% physicians** would switch only 5% non-inhibitor clients to ACE910 within 5 years
 - Clinical safety data and physician conservatism, patient push to switch
 - **63% physicians** wanted 5 years of clinical safety data before switching patient

| Q | |
|---|--|
| | |

SELECTION

CONCLUSIONS

- Trading significantly below global peers
- Like the business (diversified revenue, strong market share, significant free cash flow generation)
- Market overestimating the erosion to sales in Haemophilia franchise due to competition from Roche ACE910
- Market misunderstands the quality of the Baxalta bioplasma assets (acquired June 2016).
- EPS growth 7-10% p.a.
- Net Debt/EBITDA to be 2-3x by end of FY2017

PIC started buying in June 2017, on a P/E ~10x and FCF yield 12%

PORTFOLIO POSITIONING STOCKS WE LIKE




| COMPANY | RATIONALE | MULTIPLE | |
|--------------|--|--|--|
| THE 🛞 STAR | Growth in assets with key casinos and hotels built with partners, ability to grow dividend over the next 5 years. | PE 16x, 1.4x P/B, DY 3.5% EV/EBITDA 8.5x. | |
| Woolworths | Dominates 'last mile' in retail, positive operating momentum, actively managing Big W losses, good balance sheet. | PE 17x, 12x EBIT, DY 3.5% \$1.80 p.s of franking credits on balance sheet. | |
| 🔗 Oil Search | High quality, good management, cyclical trade, structured to take advantage of short LNG, One of the lowest cost positions in the global LNG market. | NPV \$8.50, P/FCF 7x, Ability to double production. | |
| AXA | Low price-to-book (P/B) and leverage to rising EU/US interest rates, future dividend growth + future buybacks. | PE 10x, DY 4.7%, PB 1.0, EPS Growth 5% | |
| Shire | Rare disease drug company, One of the leading Global Bioplasma Companies, significant free cash flow (FCF) generation. | PE 10x, FCF Yield 11% EPS Growth 7-10%. | |

ALLOCATION OF INVESTMENTS AS AT 30 SEPTEMBER 2017

83% of the Portfolio's capital invested in securities

Cash is used to protect the portfolio and take advantage of attractive opportunities

Patient and prudent investment style has rewarded shareholders





- Australian securities 59%
- Global securities 24%

Cash - 17%

INVESTMENT PERFORMANCE AS AT 30 SEPTEMBER 2017



| AS AT 30 SEP 2017 | 1 MTH | 3 MTHS | 6 MTHS | 1 YR P.A. | 2 YRS P.A | SINCE INCEPTION P.A. |
|--|--------|--------|--------|-----------|-----------|-------------------------|
| PIC Investment Portfolio¹ Net of fees, expenses and before tax paid | 1.72% | 2.96% | 5.03% | 13.12% | 11.66% | 9.21% |
| S&P/ASX 300 Accumulation Index | 0.04% | 0.80% | -0.78% | 9.02% | 11.22% | 8.10% |
| Excess Returns | +1.68% | +2.16% | +5.81% | +4.10% | +0.44% | +1.11% |

¹.Returns have been calculated on the growth of Net Tangible Assets (NTA) after taking into account all operating expenses (including management fees) and assuming reinvestment of dividends and excluding tax paid. Any provisions for deferred tax on set up costs and on unrealised gains and losses are excluded.

Past performance is not indicative of future performance. Inception date is 18 December 2014.

Source: Perpetual Equity Investment Company Limited



Questions?





Shareholder services





SHAREHOLDER SERVICES

www.perpetualequity.com.au



Subscribe to email alerts



View monthly portfolio holdings and reports (released on the 14th of each month)



Daily NTA Reports keep you informed by disclosing the net asset backing per share each day

FOR ALL SHAREHOLDER REGISTRY QUERIES

Contact Link Market Services

Phone1300 554 474Emailpic@linkmarketservices.com.au

PERPETUAL

VESTMENT

EQUITY

COMPAN

KEY CONTACTS



Perpetual Investment Management Limited



AARON RUSSELL Head of Wholesale Business +61 403 473 327 aaron.russell@perpetual.com.au







TIM MCCALLUM WA State Manager +61 411 209 403 tim.mccallum@perpetual.com.au



TONY HARTE QLD State Manager +61 407 708 109 tony.harte@perpetual.com.au



ANNE ROZENAUERS Investor Relations +61 2 9229 3528 anne.rozenauers@perpetual.com.au

Level 18 Angel Place, 123 Pitt Street SYDNEY NSW 2000 Australia



OR call Link Market Services on +61 1800 421 712, or email pic@linkmarketservices.com.au